Abington Memorial Hospital and our Neurosciences Institute is a site for the international ATACH-II trial, sponsored by the National Institutes of Health and the Stroke Center at the University of Minnesota. AMH is among 50 centers both nationally and internationally which are participating in this trial.
AMH has the distinction of having enrolled the first patient in this national trial. As of December 2011, Dr. Shah has enrolled five patients (almost half of the 11 patients entered nationally). According to Qaisar A. Shah, MD, director of Neurointerventional and Neurocritical Care, “A great deal of effort in a short period of time is required to enroll a patient because the enrollment is time sensitive (within three hours from the time of onset of stroke symptoms). However, because of our expedited stroke alert system and coordination of various teams the task became easier.”
The purpose of the study is to determine the therapeutic benefit of intensive systolic blood pressure (SBP) treatment (SBP=140 mmHg) compared with standard SBP treatment (SBP=180 mmHg) in reducing the proportion of patients with death and disability [modified Rankin Scale (mRS) of 4-6] at three months among intracerebral hemorrhage subjects treated within three hours of symptom onset.